Strokes caused by an artery tear are landing five times as many Americans in the hospital these days, a new study says.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Lepodisiran is being developed by biotech giant Eli Lilly & Co. (LLY), a stock that’s in my model portfolio. Here’s the tale of this new drug…how it could help millions of heart-ailment sufferers…and ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition affecting the left ventricle, the main p ...

A single dose of an experimental drug has been found to reduce the risk of genetic heart disease by at least 94 per cent.

Eli Lilly’s experimental drug lepodisiran has shown a 94% reduction in lipoprotein(a) levels, a key genetic risk factor for ...

New drug shows promise in lowering Lp(a), a hidden heart risk factor. Especially vital for Black Americans, who often have ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

A new drug may help protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the ...